Earnings, Sales Blow Past Estimates
Five Below earned $0.11 a share in the second quarter of sales of $117 million. Analysts had only expected $0.09 and $112.7 million, respectively. It also raised full-year guidance, sending FIVE up 13 percent before the opening bell on my tradeMONSTER platform.
PVH Drops on Weak Outlook
PVH's earnings and revenue both beat expectations, but the guidance was another story! Third-quarter profit is seen at $2.20 a share and sales will be $2.20 billion. Analysts had been modeling $2.30 and $2.23, respectively. PVH tumbles 5 percent in the premarket.
Drugs Data Sends Neurocrine Lower
Neurocrine Bioscience said that its NBI-98854 failed to meet primary endpoints in a Phase II study of the compound as a treatment for people suffering from involuntary movements. That's bad news for a company with no products in the market! NBIX craters 25 percent in early trading.
More From optionMONSTER